Managing Lung Cancer with Comorbid Interstitial Pneumonia.

Managing Lung Cancer with Comorbid Interstitial Pneumonia. Intern Med. 2019 Sep 18;: Authors: Ichihara E, Miyahara N, Maeda Y, Kiura K Abstract Systemic therapy for advanced non-small cell lung cancer (NSCLC) has dramatically changed in the latest 15 years. Molecular-targeted therapy has brought about an era of precision medicine, and immune checkpoint inhibitors have brought hope for a cure for advanced NSCLC. In the wake of this remarkable advancement, lung cancer with comorbid interstitial pneumonia (IP) has been completely left behind, as most clinical trials exclude patients with comorbid IP. IP, especially idiopathic pulmonary fibrosis (IPF), is often accompanied by lung cancer, and acute exacerbation can develop during various cancer therapies, including surgery, radiotherapy and pharmacotherapy. In this review, we focus on the clinical questions concerning pharmacotherapy in cases of advanced lung cancer with comorbid IP and discuss what we can do with the currently available data. PMID: 31534086 [PubMed - as supplied by publisher]
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research

Related Links:

Conclusion: In this real-world subgroup analysis of Korean patients in the ASTRIS study, osimertinib demonstrated comparable clinical efficacy to that attained in the global ASTRIS study and other clinical trials, with no new safety concerns. PMID: 31581843 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
ConclusionsCeritinib demonstrated a clinically meaningful efficacy and a safety profile similar to earlier reported results in this largest reported set of ALK+ NSCLC pts with LM.Clinical trial identificationNCT02336451.Editorial acknowledgementAarti Kamaraj, Novartis Healthcare Pvt Ltd (Hyderabad, India).Legal entity responsible for the studyNovartis Pharmaceuticals.FundingNovartis Pharmaceuticals.DisclosureF. Barlesi: Honoraria (self): AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer –Ingelheim, Eli Lilly Oncology; Honoraria (self): F. Hoffmann–La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, Pfizer and ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsPatients with NSCLC with these factors for poor prognosis of nivolumab-induced ILD should be monitored for ILD during nivolumab treatment.Editorial acknowledgementMedical writing assistance was provided by Justine Southby, PhD, CMPP, and Hiroko Ebina, BPharm, Ph, MBA, of ProScribe – Envision Pharma Group, and was funded by Ono Pharmaceutical Co., Ltd.Legal entity responsible for the studyOno Pharmaceutical Co., Ltd.FundingOno Pharmaceutical Co., Ltd., Osaka, Japan, and Bristol-Myers Squibb K.K., Tokyo, Japan.DisclosureK. Oikado: Honoraria (self): Ono Pharmaceutical ; Honoraria (self): AstraZeneca. Y. Saito...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: LIFA exhibited dose-proportional pharmacokinetics and an acceptable safety profile, with encouraging activity in PROC patients at the single-agent RP2D of 2.4 mg/kg. PMID: 31540980 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
ConclusionsDecrease in the rates of perioperative outcomes parallels improvements in patient selection and perioperative management of early-stage NSCLC resection patients. Predictors of pulmonary complication could be used to improve selection criteria for surgery and to reduce the incidence of pulmonary complication in these patients.
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
CONCLUSIONS: Decrease in the rates of perioperative outcomes parallels improvements in patient selection and perioperative management of early-stage NSCLC resection patients. Predictors of pulmonary complication could be used to improve selection criteria for surgery and to reduce the incidence of pulmonary complication in these patients. PMID: 31539514 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Surg Source Type: research
ConclusionsThe primary end point of this study was not achieved. However, the therapy was well tolerated and may be a treatment option for a future study with patients responsive to short-term erlotinib treatment.Clinical trials registration numberUMIN ID: 000013125.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Conclusion Crizotinib can be used for the treatment of advanced NSCLC with ALK fusion/translocation. It is highly effective and well tolerated. 
 DOI: 10.3779/j.issn.1009-3419.2019.08.02
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
Publication date: Available online 14 August 2019Source: The Annals of Thoracic SurgeryAuthor(s): Keita Nakao, Masaki Anraku, Takahiro Karasaki, Kentaro Kitano, Kazuhiro Nagayama, Masaaki Sato, Jun NakajimaAbstractBackgroundLung cancer patients with a history of treatment often undergo curative surgical resection. However, the impact of previous cancer treatment history on the outcome of lung cancer remains unclear.MethodsWe conducted a retrospective study of patients who underwent curative resection for non-small cell lung cancer between 1998 and 2011. We collected clinicopathological data and patients were divided into g...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Abstract BACKGROUND: Lung cancer patients with a history of treatment often undergo curative surgical resection. However, the impact of previous cancer treatment history on the outcome of lung cancer remains unclear. METHODS: We conducted a retrospective study of patients who underwent curative resection for non-small cell lung cancer between 1998 and 2011. We collected clinicopathological data and patients were divided into groups by previous cancer treatment history. Comparisons between groups, estimation of survival rates, and multivariate analyses were performed. Propensity-score matching was used to crea...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Surg Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Clinical Trials | Internal Medicine | Lung Cancer | Non-Small Cell Lung Cancer | Pneumonia